FDA approves blinatumomab for MRD-positive acute lymphoblastic leukemia |

                  Profession
                  
Mobile 
                        
                  Speciality
                                    
                 Medical Council
                  
               Registration Number

Journal Updates

FDA approves blinatumomab for MRD-positive acute lymphoblastic leukemia

eMediNexus, 30 March 2018
1821 Views
#Hematology #Nursing #Oncology #Pathology and Lab Medicine

The US FDA has expanded the approval of blinatumomab (Blincyto) to include the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), for patients in remission who still have minimal residual disease (MRD).